Adam S. Sperling

5.9k total citations · 2 hit papers
73 papers, 2.1k citations indexed

About

Adam S. Sperling is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Adam S. Sperling has authored 73 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Hematology, 43 papers in Molecular Biology and 21 papers in Oncology. Recurrent topics in Adam S. Sperling's work include Multiple Myeloma Research and Treatments (36 papers), Protein Degradation and Inhibitors (19 papers) and CAR-T cell therapy research (14 papers). Adam S. Sperling is often cited by papers focused on Multiple Myeloma Research and Treatments (36 papers), Protein Degradation and Inhibitors (19 papers) and CAR-T cell therapy research (14 papers). Adam S. Sperling collaborates with scholars based in United States, France and United Kingdom. Adam S. Sperling's co-authors include Benjamin L. Ebert, Christopher J. Gibson, Nikhil C. Munshi, Max Jan, Michael Grunstein, Yu‐Tzu Tai, Mehmet Samur, Mariateresa Fulciniti, Kenneth C. Anderson and Jennifer A. Armstrong and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Adam S. Sperling

71 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia

2016 374 citations Adam S. Sperling, Christopher J. Gibson et al. profile →
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

2021 236 citations Mehmet Samur, Mariateresa Fulciniti et al. Nature Communications profile →

Peers

Countries citing papers authored by Adam S. Sperling

Since Specialization

Citations

This map shows the geographic impact of Adam S. Sperling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam S. Sperling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam S. Sperling more than expected).

Fields of papers citing papers by Adam S. Sperling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam S. Sperling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam S. Sperling. The network helps show where Adam S. Sperling may publish in the future.

Co-authorship network of co-authors of Adam S. Sperling

This figure shows the co-authorship network connecting the top 25 collaborators of Adam S. Sperling. A scholar is included among the top collaborators of Adam S. Sperling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam S. Sperling. Adam S. Sperling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy 2025 ·Blood Advances ·Jessica S Little, (unknown), (unknown), Andrew J. Yee, Omar Nadeem, Shonali Midha, Adam S. Sperling, (unknown), Noopur Raje, Matthew J. Frigault, Diana Cirstea, Sarah P. Hammond	1
2	Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma 2025 ·Journal of Clinical Oncology ·Anıl Aktaş Samur, Jill Corre, Srikanth Talluri, Parth Shah, (unknown), (unknown), (unknown), (unknown), Raphaël Szalat, Mariateresa Fulciniti, Kenneth C. Anderson, Adam S. Sperling, Giovanni Parmigiani, Hervé Avet‐Loiseau, Nikhil C. Munshi, Mehmet Samur	0
3	Long-term persistent exposure to cigarette smoke induces AhR driven corneal endothelial dysfunction in mice 2024 ·Experimental Eye Research ·Mohit Parekh, (unknown), Neha Deshpande, Peter Miller, Adam S. Sperling, Yohannes Tesfaigzi, Ula V. Jurkunas	1
4	P-045 Idecabtagene Vicleucel (ide-cel) in Patients (pts) With Clinical High-Risk Early Relapse Multiple Myeloma (MM) Without Front-Line (1L) Autologous Stem Cell Transplantation (ASCT): KarMMA-2 Cohort 2B 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Xavier Leleu, Alfred Chung, Noopur Raje, Meera Mohan, Reuben Benjamin, Adam S. Sperling, Larry Anderson, Madhav V. Dhodapkar, Shambavi Richard, Anna Truppel-Hartmann, (unknown), Fan Wu, (unknown), Ethan Thompson, Devender Dhanda, (unknown), (unknown), Maria Chaudhry, Melissa Alsina	1
5	Cytopenias in BCMA CAR T: unraveling inflammatory mechanisms 2024 ·Blood Advances ·Adam S. Sperling	1
6	Chimeric Antigen Receptor T Cells in Multiple Myeloma 2023 ·Hematology/Oncology Clinics of North America ·(unknown), Adam S. Sperling	0
7	Clonal Hematopoiesis in Young Women Treated for Breast Cancer 2023 ·Clinical Cancer Research ·Christopher J. Gibson, Geoffrey Fell, Tal Sella, Adam S. Sperling, (unknown), Shoshana M. Rosenberg, Gregory J. Kirkner, (unknown), Deborah Dillon, Alexander G. Bick, Donna Neuberg, Ann H. Partridge, Peter G. Miller	15
8	High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma 2023 ·Blood ·Mehmet Samur, Marco Roncador, Anıl Aktaş Samur, Mariateresa Fulciniti, Abdul Hamid Bazarbachi, Raphaël Szalat, Masood A. Shammas, Adam S. Sperling, Paul G. Richardson, Florence Magrangeas, Stéphane Minvielle, Aurore Perrot, Jill Corre, Philippe Moreau, Anjan Thakurta, Giovanni Parmigiani, Kenneth C. Anderson, Hervé Avet‐Loiseau, Nikhil C. Munshi	22
9	Selinexor: Targeting a novel pathway in multiple myeloma 2023 ·SHILAP Revista de lepidopterología ·Clifton C. Mo, Andrew J. Yee, Shonali Midha, (unknown), Omar Nadeem, Elizabeth O’Donnell, Giada Bianchi, Adam S. Sperling, Jacob P. Laubach, Paul G. Richardson	17
10	Respiratory infections predominate after day 100 following B-cell maturation antigen–directed CAR T-cell therapy 2023 ·Blood Advances ·Jessica S Little, (unknown), Joseph Hong, Omar Nadeem, Adam S. Sperling, Noopur Raje, Nikhil C. Munshi, Matthew J. Frigault, Sara Barmettler, Sarah P. Hammond	24
11	Optimizing the manufacturing and antitumour response of CAR T therapy 2023 ·Nature Reviews Bioengineering ·Yutong Liu, Adam S. Sperling, Eric L. Smith, David Mooney	28
12	The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma 2022 ·Seminars in Oncology ·Christin B. DeStefano, Steven J. Gibson, Adam S. Sperling, Paul G. Richardson, Irene M. Ghobrial, Clifton C. Mo	4
13	Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216 2021 ·Journal of Medicinal Chemistry ·Mingxing Teng, Wenchao Lu, Katherine A. Donovan, Jialin Sun, (unknown), Radosław P. Nowak, Yen-Der Li, Adam S. Sperling, Tinghu Zhang, Benjamin L. Ebert, Eric S. Fischer, Nathanael S. Gray	34
14	Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide 2021 ·Science Translational Medicine ·Max Jan, Irene Scarfò, Rebecca C. Larson, (unknown), Andrea Schmidts, Andrew A. Guirguis, Jessica A. Gasser, Mikołaj Słabicki, Amanda A. Bouffard, Ana P. Castaño, Michael C. Kann, Maria L. Cabral, Alexander Tepper, (unknown), Adam S. Sperling, Taeyoon Kyung, Quinlan Sievers, Michael E. Birnbaum, Marcela V. Maus, Benjamin L. Ebert	180
15	A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade 2020 ·Haematologica ·Peter G. Miller, Adam S. Sperling, Christopher J. Gibson, Olga Pozdnyakova, Waihay J. Wong, Michael P. Manos, Elizabeth I. Buchbinder, F. Stephen Hodi, Benjamin L. Ebert, Matthew S. Davids	3
16	Widespread intronic polyadenylation diversifies immune cell transcriptomes 2018 ·Nature Communications ·Irtisha Singh, Shih‐Han Lee, Adam S. Sperling, Mehmet Samur, Yu‐Tzu Tai, Mariateresa Fulciniti, Nikhil C. Munshi, Christine Mayr, Christina S. Leslie	114
17	γH2A is a component of yeast heterochromatin required for telomere elongation 2011 ·Cell Cycle ·Tasuku Kitada, Thomas Schleker, Adam S. Sperling, (unknown), Susan M. Gasser, Michael Grunstein	20
18	Histone H3 Lysine 56 Acetylation Is Linked to the Core Transcriptional Network in Human Embryonic Stem Cells 2009 ·Molecular Cell ·Wei Xie, Chunying Song, Nicolas L. Young, Adam S. Sperling, Feng Xu, Rupa Sridharan, Anne E. Conway, Benjamin A. García, Kathrin Plath, Amander T. Clark, Michael Grunstein	160
19	Genetic Identification of a Network of Factors that Functionally Interact with the Nucleosome Remodeling ATPase ISWI 2008 ·PLoS Genetics ·Giosalba Burgio, Gaspare La Rocca, Anna Sala, Walter Arancio, (unknown), (unknown), Adam S. Sperling, Jennifer A. Armstrong, Simon J. van Heeringen, Colin Logie, John W. Tamkun, Davide Corona	29
20	The Drosophila BRM complex facilitates global transcription by RNA polymerase II 2002 ·The EMBO Journal ·Jennifer A. Armstrong, Ophelia Papoulas, Gary Daubresse, Adam S. Sperling, John T. Lis, Matthew P. Scott, John W. Tamkun	135

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact